Jaime Rosenberg

In a letter to CMS Administrator Seema Verma, Energy and Commerce Committee Chairman Frank Pallone Jr, D-New Jersey, and Ways and Means Committee Chairman Richard E. Neal, D-Massachusetts, have demanded information on the Trump administration’s changes to the federal marketplace, which they say can cause confusion for enrollees, weaken consumer protections, and further compromise the Affordable Care Act (ACA).

A pilot study is suggesting that ruxolitinib is safe and tolerable as maintenance therapy following allogeneic stem cell transplantation.

During the Center for Strategic & International Studies’ event “HIV/AIDS in the Unites States: The Road to 2030,” Anthony S. Fauci, MD, director of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, and Robert Redfield, MD, director, CDC, joined to explain why the country is ready and able to end the epidemic from both a policy and clinical perspective.

Outlining a set of issues that need to be addressed under the Oncology Care Model (OCM), the Community Oncology Alliance (COA) is urging the Center for Medicare & Medicaid Innovation to delay the October 2019 deadline for practices to transition to 2-sided risk under the model.

Results of the CLL14 trial, which were presented today at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois, resulted in the approval of the venetoclax combination for these patients in May.

People living with HIV are generally at 1.5- to 2-fold higher risk for cardiovascular diseases (CVDs), including heart attacks, strokes, and heart failure, and they often face barriers to accessing care.

This is part 3 of a 3-part vaccine series covering the potential of vaccines for infectious diseases, the impact of the antivaccination movement, and the promise of vaccines for cancer treatment. Read part 1 and part 2.

Nearly 10% of people living with HIV have to travel more than an hour to access HIV care, and those living in rural counties have drive times more than double that of those in urban counties.

The median lag time from first-in-human to first-in-child trials of oncology drugs that were ultimately approved by FDA is 6.5 years.

Chronic obstructive pulmonary disease (COPD) is associated with shorter survival and marked differences in early stages of non-small cell lung cancer (NSCLC).

A study has found that 28% of men and 26% of women between the ages of 35 and 50 years have osteopenia and are at risk for osteoporosis.

AveXis—a Novartis company—announced that it will work with payers to implement 5-year outcomes-based agreements and novel pay-over-time options. The company also said it will offer a patient program to support affordability and access.

By 2060, an estimated 48 million people each year will die with serious health-related suffering, representing an 87% increase from 2016.

A study has identified links between osteoporosis and hypertension, coronary heart disease, and cerebral infarction.

Venetoclax (Venclexta) has received FDA approval in combination with obinutuzumab (Gazyva) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), offering a chemotherapy-free regimen for patients with previously untreated disease.

Blood eosinophil (EOS) counts of 150 cells/mcL or greater were associated with increased chronic obstructive pulmonary disease (COPD)–related healthcare resource utilization compared with EOS counts less than 150 cells/mcL, regardless of multiple inhaler triple therapy use.

Voxelotor, a first-in-class oral therapy, is both safe and effective in sickle cell disease, according to a phase 1/2 randomized study assessing the drug. These findings were consistent across all doses, ranging from 500 to 1000 mg.

Patients with primary care appointments in the morning were more likely to have orders for and receive recommended breast and colorectal cancer screenings.

Damage to mitochondria, which can occur from exposure to cigarette smoke and environmental pollutants, leads to a surge in the creation of osteoclasts that break down bone.

Researchers have identified a new target in the mitochondria of cancer cells that indicate the potential of a treatment class for certain blood cancers.

HHS has announced that Gilead will donate its pre-exposure prophylaxis (PrEP) pill Truvada for up to 200,000 people in a multiyear agreement, just a day after the pharma giant announced that a generic version of the pill will come to market a year early. However, some activists are skeptic.

Between 2004 and 2017, the annual number of fall-related fractures from walking leashed dogs increased from 1671 to 4396 among adults aged 65 years or older.

The FDA has approved amifampridine (Ruzurgi), the first treatment for pediatric patients with Lambert-Eaton myasthenic syndrome.

President Trump today outlined a plan to tackle surprise medical billing and voiced his commitment to holding insurance companies and hospitals accountable.

The number of patients requiring first-line chemotherapy is expected to increase by more than 50% from 2018 to 2040, and in order to deliver optimal treatment, a significant increase in the chemotherapy workforce is needed.

An analysis of adoption of and adherence to chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in the primary care setting unearthed disappointing results, finding suboptimal use of pulmonary function tests, no routine use of validated symptoms scales for diagnosis, and variation in pharmacotherapy.

The Trump administration on Wednesday announced a final rule requiring drug manufacturers to disclose drug prices in television ads for drugs covered by Medicare or Medicaid if the wholesale acquisition cost is $35 or more for a month’s supply.

Researchers from the University of Buffalo surveyed pharmacist students, finding high awareness of pre-exposure prophylaxis (PrEP) and generally positive attitudes towards it. However, the survey also revelaed gaps in knowledge, highlighting the need for more education.

During World Health Care Congress 2019, healthcare stakeholders from around the globe convened to discuss all things healthcare, ranging from Medicare for All to social determinants of health.

According to the FDA, there is not enough data to ban sales of textured breast implants that have been associated with a rare cancer.